Technical Analysis for NUVL - Nuvalent, Inc.

Grade Last Price % Change Price Change
F 12.66 7.38% 0.87
NUVL closed down 7.17 percent on Tuesday, January 18, 2022, on 2.59 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down
Historical NUVL trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 7.38%
180 Bearish Setup Bearish Swing Setup 7.38%
New 52 Week Low Weakness 7.38%
Wide Bands Range Expansion 7.38%
Oversold Stochastic Weakness 7.38%
New 52 Week Low Weakness -0.31%
Wide Bands Range Expansion -0.31%
Oversold Stochastic Weakness -0.31%
New 52 Week Closing Low Bearish 4.11%
NR7 Range Contraction 4.11%
Older End-of-Day Signals for NUVL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 10% 15 minutes ago
Rose Above Previous Day's High 31 minutes ago
Up 5% 31 minutes ago
60 Minute Opening Range Breakout about 2 hours ago
Up 3% about 2 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Nuvalent, Inc. Description

Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Chemical Compounds Organic Compounds Tyrosine Kinase Receptors Preclinical Stage Biopharmaceutical Therapies For Patients With Cancer Entrectinib

Is NUVL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 40.715
52 Week Low 11.69
Average Volume 95,017
200-Day Moving Average 0.00
50-Day Moving Average 20.56
20-Day Moving Average 16.79
10-Day Moving Average 14.18
Average True Range 1.76
ADX 34.78
+DI 7.12
-DI 28.73
Chandelier Exit (Long, 3 ATRs) 18.56
Chandelier Exit (Short, 3 ATRs) 16.98
Upper Bollinger Bands 22.93
Lower Bollinger Band 10.65
Percent B (%b) 0.09
BandWidth 73.17
MACD Line -2.43
MACD Signal Line -1.95
MACD Histogram -0.4729
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.39
Resistance 3 (R3) 13.53 13.14 13.12
Resistance 2 (R2) 13.14 12.74 13.07 13.03
Resistance 1 (R1) 12.47 12.49 12.27 12.32 12.94
Pivot Point 12.08 12.08 11.98 12.01 12.08
Support 1 (S1) 11.40 11.67 11.21 11.26 10.64
Support 2 (S2) 11.01 11.42 10.94 10.55
Support 3 (S3) 10.34 11.01 10.46
Support 4 (S4) 10.19